GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Total Valuation
GlaxoSmithKline Pharmaceuticals Limited has a market cap or net worth of ₹405.43B. The enterprise value is ₹398.44B.
Market Cap₹405.43B
Enterprise Value₹398.44B
Share Statistics
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169,406,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GlaxoSmithKline Pharmaceuticals Limited’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is 37.12%.
Return on Equity (ROE)0.48
Return on Assets (ROA)0.23
Return on Invested Capital (ROIC)37.12%
Return on Capital Employed (ROCE)0.51
Revenue Per Employee11.60M
Profits Per Employee2.89M
Employee Count3,211
Asset Turnover0.91
Inventory Turnover3.06
Valuation Ratios
The current PE Ratio of GlaxoSmithKline Pharmaceuticals Limited is 35.4. GlaxoSmithKline Pharmaceuticals Limited’s PEG ratio is 0.89.
PE Ratio35.4
PS Ratio12.72
PB Ratio24.29
Price to Fair Value24.29
Price to FCF37.41
Price to Operating Cash Flow220.73
PEG Ratio0.89
Income Statement
In the last 12 months, GlaxoSmithKline Pharmaceuticals Limited had revenue of 37.26B and earned 9.28B in profits. Earnings per share was 54.76.
Revenue37.26B
Gross Profit22.53B
Operating Income11.14B
Pretax Income12.60B
Net Income9.28B
EBITDA13.28B
Earnings Per Share (EPS)54.76
Cash Flow
In the last 12 months, operating cash flow was 1.84B and capital expenditures -170.40M, giving a free cash flow of 1.67B billion.
Operating Cash Flow1.84B
Free Cash Flow1.67B
Free Cash Flow per Share9.84
Dividends & Yields
GlaxoSmithKline Pharmaceuticals Limited pays an annual dividend of ₹42, resulting in a dividend yield of 2.16%
Dividend Per Share₹42
Dividend Yield2.16%
Payout Ratio75.81%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change-15.72%
50-Day Moving Average2.46K
200-Day Moving Average2.68K
Relative Strength Index (RSI)49.96
Average Volume (3m)1.83K
Important Dates
GlaxoSmithKline Pharmaceuticals Limited upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateFeb 9, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline Pharmaceuticals Limited as a current ratio of 1.79, with Debt / Equity ratio of 2.09%
Current Ratio1.79
Quick Ratio1.54
Debt to Market Cap0.00
Net Debt to EBITDA-0.40
Interest Coverage Ratio944.92
Taxes
In the past 12 months, GlaxoSmithKline Pharmaceuticals Limited has paid 3.32B in taxes.
Income Tax3.32B
Effective Tax Rate0.26
Enterprise Valuation
GlaxoSmithKline Pharmaceuticals Limited EV to EBITDA ratio is 35.29, with an EV/FCF ratio of 36.99.
EV to Sales12.58
EV to EBITDA35.29
EV to Free Cash Flow36.99
EV to Operating Cash Flow36.33
Balance Sheet
GlaxoSmithKline Pharmaceuticals Limited has ₹20.61B in cash and marketable securities with ₹357.10M in debt, giving a net cash position of ₹20.25B billion.
Cash & Marketable Securities₹20.61B
Total Debt₹357.10M
Net Cash₹20.25B
Net Cash Per Share₹119.55
Tangible Book Value Per Share₹114.40
Margins
Gross margin is 57.73%, with operating margin of 29.91%, and net profit margin of 24.89%.
Gross Margin57.73%
Operating Margin29.91%
Pretax Margin33.81%
Net Profit Margin24.89%
EBITDA Margin35.64%
EBIT Margin33.85%
Analyst Forecast
The average price target for GlaxoSmithKline Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast4.17%
EPS Growth Forecast41.51%